Clinical Trial: Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517640) titled 'Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial' on March 25.

Brief Summary: The goal of this Single-arm, Phase II clinical trial is to learn whether ablation or stereotactic radiotherapy combined with furmonertinib can treat early-stage non-small cell lung cancer in patients who are inoperable or refuse surgery.

The main purposes of this study is to answer:

Can ablation or stereotactic radiotherapy combined with furmonertinib improve survival in patients with early-stage NSCLC who are inoperable or refuse surgery? Can ablation or stereotactic radiotherapy combined with furmonert...